Results and adverse events of personalized peptide receptor radionuclide therapy with 90Yttrium and 177Lutetium in 1048 patients with neuroendocrine neoplasms.

about

Results and adverse events of personalized peptide receptor radionuclide therapy with 90Yttrium and 177Lutetium in 1048 patients with neuroendocrine neoplasms.

Item

http://www.wikidata.org/entity/Q52571250

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Results and adverse events of ...... with neuroendocrine neoplasms.

@en

Results and adverse events of ...... with neuroendocrine neoplasms.

@nl

type

Item

label

Results and adverse events of ...... with neuroendocrine neoplasms.

@en

Results and adverse events of ...... with neuroendocrine neoplasms.

@nl

prefLabel

Results and adverse events of ...... with neuroendocrine neoplasms.

@en

Results and adverse events of ...... with neuroendocrine neoplasms.

@nl

P1476

Results and adverse events of ...... with neuroendocrine neoplasms.

@en

P2093

Arthur Jochems

http://www.w3.org/2001/XMLSchema#string

Aviral Singh

http://www.w3.org/2001/XMLSchema#string

Daniel Kaemmerer

http://www.w3.org/2001/XMLSchema#string

Dieter Hörsch

http://www.w3.org/2001/XMLSchema#string

Dirk Mueller

http://www.w3.org/2001/XMLSchema#string

Franz C Robiller

http://www.w3.org/2001/XMLSchema#string

Harshad R Kulkarni

http://www.w3.org/2001/XMLSchema#string

Holger Franz

http://www.w3.org/2001/XMLSchema#string

Karin Niepsch

http://www.w3.org/2001/XMLSchema#string

Merten Hommann

http://www.w3.org/2001/XMLSchema#string

P2860

Radiolabeling of DOTA-like conjugated peptides with generator-produced (68)Ga and using NaCl-based cationic elution method.

Long-term hematotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate.

Pancreatic Neuroendocrine Tumor Control: Durable Objective Response to Combination 177Lu-Octreotate-Capecitabine-Temozolomide Radiopeptide Chemotherapy.

NeuroEndocrine Tumor Therapy with Lutetium-177-octreotate and Everolimus (NETTLE): A Phase I Study.

Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors.

Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group.

[(177)Lu-DOTA](0)-D-Phe(1)-Tyr(3)-Octreotide ((177)Lu-DOTATOC) For Peptide Receptor Radiotherapy in Patients with Advanced Neuroendocrine Tumours: A Phase-II Study.

The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours

Nephrotoxicity after PRRT with (177)Lu-DOTA-octreotate

Safety and Efficacy of 68Ga-DOTATATE PET/CT for Diagnosis, Staging, and Treatment Management of Neuroendocrine Tumors

P304

16932-16950

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.24524

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-02-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29682195

http://www.w3.org/2001/XMLSchema#string

P932

5908296

http://www.w3.org/2001/XMLSchema#string